Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Micromedic Technologies

New Line of Single-Use Bags Meets Stringent Requirements of the Biopharmaceutical Industry

By BiotechDaily International staff writers
Posted on 19 Jun 2014
Print article
Image: Flexsafe represents a completely new generation of single-use bags that offer consistent cell growth as well as extraordinary robustness and flexibility (Photo courtesy of Sartorius Stedim Biotech).
Image: Flexsafe represents a completely new generation of single-use bags that offer consistent cell growth as well as extraordinary robustness and flexibility (Photo courtesy of Sartorius Stedim Biotech).
A major global supplier of laboratory products for the biopharmaceutical industry has begun marketing a new range of single-use bags in a multitude of sizes and shapes.

Sartorius Stedim Biotech (Goettingen, Germany) has announced the release of its line of Flexsafe single-use bags. Flexsafe, which is based on S80, a multilayer, proprietary polyethylene (PE) film, was developed in close collaboration with resin and film suppliers. The PE film is 400 micrometers thick, making Flexsafe one of the strongest and most flexible bags currently on the market.

Optimization of resin formulation, complete control of raw materials quality, the extrusion process, and bag assembly guarantee lot-to-lot consistent cell growth performance of even the most sensitive cell lines.

Flexsafe bags are safe and easy to manage, even for the most demanding applications such as liquid shipping and large-scale stirred bioreactors. Batch-to-batch consistent extractables and leachables profiles, which support drug manufacture throughout all processes from clinical development to commercial supply, guarantee that initial extractable and leachable qualification data will remain valid for every operation involving single-use Flexsafe bioprocess products.

"Flexsafe represents a completely new generation of single-use bags," said Stefan Schlack, senior vice president marketing and product management at Sartorius Stedim Biotech. "They offer our customers consistent cell growth as well as extraordinary robustness and flexibility. In addition a sustainable supply chain and consistent film throughout the entire manufacturing process is guaranteed. Every single one of these benefits sets a new benchmark. Being unique in all of them makes us very proud.”

Initially Sartorius Stedim Biotech is launching Flexsafe RM bags (1–200 liters) and small bags for validation purposes. Bags for single use bioreactors BIOSTAT STR (50–2,000 liters) and additional applications such as storage, mixing, shipping, freezing and thawing will be introduced over the coming months.

Related Links:

Sartorius Stedim Biotech 



Print article

Channels

Genomics/Proteomics

view channel
Image: Top: Overview of the structure of T-STAR STAR domain in complex with AUUAAA RNA. Bottom left: close up view of the specific recognition of the RNA. Bottom right: close up view of the KH dimerization interface (Photo courtesy of the University of Leicester).

Atomic Structures of Alternative Splicing Regulator Proteins May Lead to New Anticancer Drugs

A detailed structural analysis of two RNA-binding proteins that regulate alternate splicing of gene expression, which can lead to various types of cancer, is expected to aid in the development of drugs... Read more

Drug Discovery

view channel
Image: Naturally occurring clay from Kisameet Bay, Canada, exhibits potent antibacterial activity against multidrug-resistant pathogens (Photo courtesy of Kisameet Glacial Clay Inc.).

Antibiotic Resistant Bacteria Succumb to Treatment with Unique Natural Clay

A team of Canadian medical microbiologists has demonstrated the potential use of a unique type of natural clay for treating pathogenic bacteria that have become resistant to the commonly used antibiotics.... Read more

Business

view channel

Purchase Agreement to Boost Ebola Vaccine Development

A deal to help boost development of a vaccine to protect against Ebolavirus infection was finalized at the recent Davos Conference in Switzerland. Gavi (Geneva, Switzerland), the global alliance for vaccines and immunizations, announced that it would spend five million USD to purchase the Ebola vaccine under development... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.